.jpg "Anomalies discovered at the bottom of the Indian Ocean, possibly the location of the MH370 crash")
.jpg "Real estate market in the south of Hai Duong city is bustling")
.jpg "Extremely dangerous forest fire risk in Kinh Mon, Chi Linh")
-ac017d3d3ce25d3405471795d6bb26f0.jpg "Gia Loc needs over 10 billion VND to invest in renovating and expanding landfills.")
Submit a comment
According to research by scientists at Stanford University (USA), treatment with Pfizer's antiviral drug Paxlovid for 15 days does not reduce prolonged COVID-19 symptoms.
To date, there is no proven treatment for long-term COVID-19, in which symptoms can persist for months after the initial infection. Scientists and patients had hoped Pfizer’s oral drug would help relieve long-term COVID-19 symptoms after some patients said Paxlovid worked.
Stanford University scientists conducted a 15-day study of 155 people who had symptoms for more than 16 months before enrolling in the trial. The results showed that taking Paxlovid for 15 days did not help reduce symptoms of fatigue, brain fog, shortness of breath, body aches, digestive problems, or cardiovascular symptoms.
Stanford professor of medicine Dr. Upinder Singh said the team of scientists did not find that the drug was effective in reducing all six symptoms or any single symptom of the patient. Ms. Singh said that scientists need to study more about the treatment of COVID-19 syndrome with Paxlovid for more than 15 days or in patients who have had this syndrome for a short time.
Research has shown that Paxlovid is safe for patients when used for 15 days. It is currently prescribed for 5 days and immediately after the onset of symptoms or illness.
In a statement, Pfizer said the results will not affect other collaborative research plans on Paxlovid's potential in treating long-term COVID-19.
In the United States, Paxlovid is the most commonly prescribed drug for COVID-19. It has been approved for use in adults with COVID-19 who are at risk of severe complications.
